Click here to get full coverage on I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight - Women's Health

I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight  Women's Health

I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight - Women's Health

Click here to get full coverage on Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease - Yahoo Finance

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease  Yahoo Finance

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease - Yahoo Finance

Click here to get full coverage on TIME100 Most Influential Companies 2025: Qure.ai - Time Magazine

TIME100 Most Influential Companies 2025: Qure.ai  Time Magazine

TIME100 Most Influential Companies 2025: Qure.ai - Time Magazine

Click here to get full coverage on uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE)  Seeking Alpha

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha

Click here to get full coverage on uniQure (QURE): Examining Valuation Following Positive Huntington’s Disease Gene Therapy Results - simplywall.st

uniQure (QURE): Examining Valuation Following Positive Huntington’s Disease Gene Therapy Results  simplywall.st

uniQure (QURE): Examining Valuation Following Positive Huntington’s Disease Gene Therapy Results - simplywall.st

Click here to get full coverage on QURE Stock To $500? - Forbes

QURE Stock To $500? - Forbes

Click here to get full coverage on uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts  MarketBeat

uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Click here to get full coverage on I Tried the TikTok-Viral Microneedling System — and It’s 70% Off Right Now - Popsugar

I Tried the TikTok-Viral Microneedling System — and It’s 70% Off Right Now  Popsugar

I Tried the TikTok-Viral Microneedling System — and It’s 70% Off Right Now - Popsugar

Click here to get full coverage on uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ  StocksToTrade

uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Click here to get full coverage on Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says - Reuters

Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says  Reuters

Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says - Reuters

Click here to get full coverage on HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq

HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation  Nasdaq

HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq

Click here to get full coverage on SSO Cancer Hospital in partnership with EPIC Hospital launches Qure.ai’s AI tool for early cancer detection - Pharmabiz.com

SSO Cancer Hospital in partnership with EPIC Hospital launches Qure.ai’s AI tool for early cancer detection  Pharmabiz.com

SSO Cancer Hospital in partnership with EPIC Hospital launches Qure.ai’s AI tool for early cancer detection - Pharmabiz.com

Click here to get full coverage on uniQure (NASDAQ:QURE) Sets New 12-Month High - Time to Buy? - MarketBeat

uniQure (NASDAQ:QURE) Sets New 12-Month High - Time to Buy?  MarketBeat

uniQure (NASDAQ:QURE) Sets New 12-Month High - Time to Buy? - MarketBeat

Click here to get full coverage on uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission - Yahoo Finance

uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission  Yahoo Finance

uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission - Yahoo Finance

Click here to get full coverage on Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat

Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE)  MarketBeat

Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat

Click here to get full coverage on A Fresh Look at uniQure (QURE) Valuation Following Unexplained Share Price Move - Yahoo Finance

A Fresh Look at uniQure (QURE) Valuation Following Unexplained Share Price Move  Yahoo Finance

A Fresh Look at uniQure (QURE) Valuation Following Unexplained Share Price Move - Yahoo Finance

Click here to get full coverage on QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Yahoo Finance

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study  Yahoo Finance

QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study - Yahoo Finance

Click here to get full coverage on This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now? - Yahoo Finance

This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now?  Yahoo Finance

This Stock Is Tripling on a Key Gene Therapy Win. Should You Buy the 200%-Plus Surge Now? - Yahoo Finance

Click here to get full coverage on UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com

UniQure’s Unexpected Surge: Analyzing QURE’s Performance  timothysykes.com

UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com

Click here to get full coverage on $200 Million Share Offering: Gene Therapy Leader uniQure Seeks Capital for Transformative Therapies - Stock Titan

$200 Million Share Offering: Gene Therapy Leader uniQure Seeks Capital for Transformative Therapies  Stock Titan

$200 Million Share Offering: Gene Therapy Leader uniQure Seeks Capital for Transformative Therapies - Stock Titan

Click here to get full coverage on New Analyst Forecast: $QURE Given $80.0 Price Target - Quiver Quantitative

New Analyst Forecast: $QURE Given $80.0 Price Target  Quiver Quantitative

New Analyst Forecast: $QURE Given $80.0 Price Target - Quiver Quantitative

Click here to get full coverage on $QURE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

$QURE stock is down 9% today. Here's what we see in our data.  Quiver Quantitative

$QURE stock is down 9% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on uniQure N.V. (QURE) Price Target Increased by 88.86% to 69.17 - Nasdaq

uniQure N.V. (QURE) Price Target Increased by 88.86% to 69.17  Nasdaq

uniQure N.V. (QURE) Price Target Increased by 88.86% to 69.17 - Nasdaq

Click here to get full coverage on Wells Fargo Maintains uniQure N.V. (QURE) Overweight Recommendation - Nasdaq

Wells Fargo Maintains uniQure N.V. (QURE) Overweight Recommendation  Nasdaq

Wells Fargo Maintains uniQure N.V. (QURE) Overweight Recommendation - Nasdaq

Click here to get full coverage on uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat

uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade  MarketBeat

uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat

Click here to get full coverage on 75% Disease Slowing: uniQure's Gene Therapy AMT-130 Achieves Landmark Results in Huntington's Treatment - Stock Titan

75% Disease Slowing: uniQure's Gene Therapy AMT-130 Achieves Landmark Results in Huntington's Treatment  Stock Titan

75% Disease Slowing: uniQure's Gene Therapy AMT-130 Achieves Landmark Results in Huntington's Treatment - Stock Titan

Click here to get full coverage on Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? - Nasdaq

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength?  Nasdaq

Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? - Nasdaq

Click here to get full coverage on uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - Yahoo Finance

uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company  Yahoo Finance

uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company - Yahoo Finance

Click here to get full coverage on Javier J. Zulueta joins Qure.ai as CMO - The Cancer Letter

Javier J. Zulueta joins Qure.ai as CMO  The Cancer Letter

Javier J. Zulueta joins Qure.ai as CMO - The Cancer Letter

Click here to get full coverage on Insider Sale: CEO of $QURE Sells 5,022 Shares - Quiver Quantitative

Insider Sale: CEO of $QURE Sells 5,022 Shares  Quiver Quantitative

Insider Sale: CEO of $QURE Sells 5,022 Shares - Quiver Quantitative

Click here to get full coverage on Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding - simplywall.st

Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding  simplywall.st

Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding - simplywall.st

Click here to get full coverage on QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened - Stocktwits

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened  Stocktwits

QURE Stock Jumped A Whopping 161% Pre-Market – Here’s What Happened - Stocktwits

Click here to get full coverage on uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - Yahoo Finance

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...  Yahoo Finance

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - Yahoo Finance

Click here to get full coverage on Global Healthcare Innovator Qure.ai Expands Executive Team With Eminent Lung Health Appointment to Accelerate Clinical Strategy - Business Wire

Global Healthcare Innovator Qure.ai Expands Executive Team With Eminent Lung Health Appointment to Accelerate Clinical Strategy  Business Wire

Global Healthcare Innovator Qure.ai Expands Executive Team With Eminent Lung Health Appointment to Accelerate Clinical Strategy - Business Wire

Click here to get full coverage on A Look at uniQure (QURE) Valuation Following Breakthrough Huntington’s Disease Data and Fresh Capital Raises - simplywall.st

A Look at uniQure (QURE) Valuation Following Breakthrough Huntington’s Disease Data and Fresh Capital Raises  simplywall.st

A Look at uniQure (QURE) Valuation Following Breakthrough Huntington’s Disease Data and Fresh Capital Raises - simplywall.st

Click here to get full coverage on New Analyst Forecast: $QURE Given $68.0 Price Target | QURE Stock News - Quiver Quantitative

New Analyst Forecast: $QURE Given $68.0 Price Target | QURE Stock News  Quiver Quantitative

New Analyst Forecast: $QURE Given $68.0 Price Target | QURE Stock News - Quiver Quantitative

Click here to get full coverage on A Cure For Huntington's Disease? UniQure Launches Nearly 250%. - Investor's Business Daily

A Cure For Huntington's Disease? UniQure Launches Nearly 250%.  Investor's Business Daily

A Cure For Huntington's Disease? UniQure Launches Nearly 250%. - Investor's Business Daily

Click here to get full coverage on Q&A with Bhargava Reddy, Chief Business Officer – Oncology at Qure.AI - citybiz

Q&A with Bhargava Reddy, Chief Business Officer – Oncology at Qure.AI  citybiz

Q&A with Bhargava Reddy, Chief Business Officer – Oncology at Qure.AI - citybiz

Click here to get full coverage on Javier Zulueta named chief medical officer at Qure.ai - AuntMinnie

Javier Zulueta named chief medical officer at Qure.ai  AuntMinnie

Javier Zulueta named chief medical officer at Qure.ai - AuntMinnie

Click here to get full coverage on RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛

RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65  富途牛牛

RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛

Click here to get full coverage on Qure.ai Unveils AIRA, an AI Co-Pilot Empowering Health Workers in LMICs, at World Health Assembly 2025 - Reuters

Qure.ai Unveils AIRA, an AI Co-Pilot Empowering Health Workers in LMICs, at World Health Assembly 2025  Reuters

Qure.ai Unveils AIRA, an AI Co-Pilot Empowering Health Workers in LMICs, at World Health Assembly 2025 - Reuters

Click here to get full coverage on $QURE stock is up 2% today. Here's what we see in our data. - Nasdaq

$QURE stock is up 2% today. Here's what we see in our data.  Nasdaq

$QURE stock is up 2% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets - TipRanks

UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets  TipRanks

UniQure (QURE) Stock Jumps 248% on Huntington’s Trial Results. Analysts Raise Price Targets - TipRanks

Click here to get full coverage on QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop - MarketBeat

QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop  MarketBeat

QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop - MarketBeat

Click here to get full coverage on UH Cleveland Medical Center Activates AI for Early Lung Cancer Identification - University Hospitals

UH Cleveland Medical Center Activates AI for Early Lung Cancer Identification  University Hospitals

UH Cleveland Medical Center Activates AI for Early Lung Cancer Identification - University Hospitals

Click here to get full coverage on Stocks making the biggest moves midday: Alibaba, Lithium Americas, Freeport-McMoRan, UniQure and more - CNBC

Stocks making the biggest moves midday: Alibaba, Lithium Americas, Freeport-McMoRan, UniQure and more  CNBC

Stocks making the biggest moves midday: Alibaba, Lithium Americas, Freeport-McMoRan, UniQure and more - CNBC

Click here to get full coverage on I Tried This At-Home Micro-Needling System—Now, My Favorite Concealers Are Collecting Dust - Who What Wear

I Tried This At-Home Micro-Needling System—Now, My Favorite Concealers Are Collecting Dust  Who What Wear

I Tried This At-Home Micro-Needling System—Now, My Favorite Concealers Are Collecting Dust - Who What Wear

Click here to get full coverage on Radiology artificial intelligence firm Qure.ai among Time Magazine’s ‘Most Influential Companies in the World’ for 2025 - Radiology Business

Radiology artificial intelligence firm Qure.ai among Time Magazine’s ‘Most Influential Companies in the World’ for 2025  Radiology Business

Radiology artificial intelligence firm Qure.ai among Time Magazine’s ‘Most Influential Companies in the World’ for 2025 - Radiology Business

Click here to get full coverage on Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Yahoo Finance

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet  Yahoo Finance

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Yahoo Finance

Click here to get full coverage on Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025 - Yahoo Finance

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025  Yahoo Finance

Qure.ai Recognized Among TIME’s 100 Most Influential Companies of 2025 - Yahoo Finance

Click here to get full coverage on Qure.ai unveils AI co-pilot for community health workers - Mobi Health News

Qure.ai unveils AI co-pilot for community health workers  Mobi Health News

Qure.ai unveils AI co-pilot for community health workers - Mobi Health News

Click here to get full coverage on Biggest stock movers Wednesday: Chinese tech stocks, LAC, QURE, and more - MSN

Biggest stock movers Wednesday: Chinese tech stocks, LAC, QURE, and more  MSN

Biggest stock movers Wednesday: Chinese tech stocks, LAC, QURE, and more - MSN

Click here to get full coverage on UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) - Seeking Alpha

UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE)  Seeking Alpha

UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) - Seeking Alpha

Click here to get full coverage on uniQure posts trial win for Huntington’s disease drug (QURE) - Seeking Alpha

uniQure posts trial win for Huntington’s disease drug (QURE)  Seeking Alpha

uniQure posts trial win for Huntington’s disease drug (QURE) - Seeking Alpha

Click here to get full coverage on uniQure (QURE) Shares Dip Amid $300 Million Public Offering Pric - GuruFocus

uniQure (QURE) Shares Dip Amid $300 Million Public Offering Pric  GuruFocus

uniQure (QURE) Shares Dip Amid $300 Million Public Offering Pric - GuruFocus

Click here to get full coverage on $345 Million Raised: Gene Therapy Leader uniQure Completes Upsized Offering for AMT-130 Launch Plans - Stock Titan

$345 Million Raised: Gene Therapy Leader uniQure Completes Upsized Offering for AMT-130 Launch Plans  Stock Titan

$345 Million Raised: Gene Therapy Leader uniQure Completes Upsized Offering for AMT-130 Launch Plans - Stock Titan

Click here to get full coverage on uniQure Announces $200 Million Proposed Public Offering - Yahoo Finance

uniQure Announces $200 Million Proposed Public Offering  Yahoo Finance

uniQure Announces $200 Million Proposed Public Offering - Yahoo Finance

Click here to get full coverage on Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it - MarketWatch

Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it  MarketWatch

Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it - MarketWatch

Click here to get full coverage on Biggest stock movers Wednesday: Chinese tech stocks, LAC, QURE, and more - Seeking Alpha

Biggest stock movers Wednesday: Chinese tech stocks, LAC, QURE, and more  Seeking Alpha

Biggest stock movers Wednesday: Chinese tech stocks, LAC, QURE, and more - Seeking Alpha

Click here to get full coverage on uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume - Here's What Happened - MarketBeat

uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume - Here's What Happened  MarketBeat

uniQure (NASDAQ:QURE) Sees Unusually-High Trading Volume - Here's What Happened - MarketBeat

Click here to get full coverage on Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Nasdaq

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet  Nasdaq

Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet - Nasdaq

Click here to get full coverage on uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Nasdaq

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?  Nasdaq

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Nasdaq

Click here to get full coverage on Here’s Why uniQure N.V. (QURE) Is Skyrocketing - Yahoo Finance

Here’s Why uniQure N.V. (QURE) Is Skyrocketing  Yahoo Finance

Here’s Why uniQure N.V. (QURE) Is Skyrocketing - Yahoo Finance

Click here to get full coverage on uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha

uniQure: Price And Value Have Caught Up (NASDAQ:QURE)  Seeking Alpha

uniQure: Price And Value Have Caught Up (NASDAQ:QURE) - Seeking Alpha

Click here to get full coverage on $300 Million Capital Raise: Gene Therapy Leader uniQure Prices Upsized Public Offering with Warrants - Stock Titan

$300 Million Capital Raise: Gene Therapy Leader uniQure Prices Upsized Public Offering with Warrants  Stock Titan

$300 Million Capital Raise: Gene Therapy Leader uniQure Prices Upsized Public Offering with Warrants - Stock Titan

Click here to get full coverage on uniQure (QURE) Sees Raised Price Target and Maintained Overweigh - GuruFocus

uniQure (QURE) Sees Raised Price Target and Maintained Overweigh  GuruFocus

uniQure (QURE) Sees Raised Price Target and Maintained Overweigh - GuruFocus

Click here to get full coverage on uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright - MarketBeat

uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright  MarketBeat

uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright - MarketBeat

Click here to get full coverage on Qure.ai secures FDA clearance for qER-Quant - AuntMinnie

Qure.ai secures FDA clearance for qER-Quant  AuntMinnie

QURE

Price Chart

Key Statistics

Technicals

About QURE

Latest News

I'm A Beauty Editor—My Favorite LED Face Mask Is 30% Off Before Prime Day Ends Tonight - Women's Health

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease - Yahoo Finance

TIME100 Most Influential Companies 2025: Qure.ai - Time Magazine

Advanced Charts

Top Gainers

Top Losers